Skip to main content
. 2022 Jul 23;12(8):1200. doi: 10.3390/jpm12081200

Figure 3.

Figure 3

Advantages (light green) and concerns (light orange) of the available hypolipidemic drugs. CNI, calcineurin inhibitors; CYP450, cytochromes P450; HDL, high-density lipoproteins; LDL, low-density lipoproteins; PCSK9, proprotein convertase subtilisin/kexin type 9.